Always up to date.
 

Our goal is to develop procedure and anatomy specific devices that lead in collaboration with our customers to predictable and superior treatment outcomes. Read on to learn more about our solutions, priorities, partnerships and how we create sustainable value with our teams.

Medartis increases sales by 21% (CER) and improves its underlying EBITDA margin to 16%

Demonstrating further market share gains, full-year 2023 sales rose by 20.5%(CER) to CHF 212.0 million. The EMEA region was the driving force with strong growth of 19.8%, exceeding the CHF 100 million...

Read more

Publication of the Annual Report 2023

The integrated Annual Report 2023, consisting of the Management Report, the extended Sustainability Report, the Corporate Governance Report, the Remuneration Report and the Financial Report, can be...

Read more

Medartis on track with 16% internal growth after 6 months

Medartis reported half-year sales of CHF 103.3 million, representing growth of 20.8% at CER. Internal growth amounted to 16.1%.The EMEA business made the largest contribution to this growth with an...

Read more